Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price

Sep 02 2017

• By Emily Hayes

Related Content

Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population

Jun 21 2010

Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Jun 28 2010

Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication

Sep 04 2017

Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement

Jul 11 2017

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Jan 06 2017

New data could revive Pfizer's Mylotarg

Dec 13 2011

A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

Jun 19 2017

Related Companies

Pfizer Inc.

Jazz Pharmaceuticals plc

Novartis AG

Seagen Inc.

Additional Topics

Approvals Drug Safety Regulation Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window